How does Lutathera work to treat gastroenteropancreatic neuroendocrine tumors?
Medically reviewed by Drugs.com. Last updated on Feb 16, 2024.
Lutathera (lutetium Lu 177 dotatate), a Lu-177-labeled somatostatin analogue, is a radioactive drug that binds to a somatostatin receptor on the gastroenteropancreatic neuroendocrine tumor to exert its cancer-killing effect.
The FDA approved Lutathera for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in January 2018. GEP-NETs are rare cancers that form in the pancreas, stomach, intestines, colon and rectum.
Drug information
- Lutathera Information for Consumers
- Lutathera prescribing info & package insert (for Health Professionals)
- Side Effects of Lutathera (detailed)
Related support groups
- Lutathera (1 questions, 4 members)
- Neuroendocrine Carcinoma (1 questions, 5 members)
- Gastroenteropancreatic Neuroendocrine Tumor (1 questions, 3 members)
